Business Wire

Prieto Introduces World’s Fastest-Charging Battery That Charges in 3 Minutes

22.5.2023 16:03:00 EEST | Business Wire | Press release

Share

Prieto Battery, Inc., a world leader in advanced lithium-ion battery technology, unveiled the most recent prototype of its patented 3D interdigitated battery that delivers groundbreaking performance:

  • 3-minute hyper-fast charge
  • Operates and charges in extremely low (-30 degrees C) and high (+100 degrees C) temperatures
  • Nonflammable

All three attributes of Prieto’s lithium-ion battery were tested and validated by a third-party accredited battery testing lab.

Hyper-Fast Charge

“Prieto’s battery will charge faster than you can fill your car’s gas tank,” said Mike Rosenberg, Prieto CEO. “When you charge your car faster than gassing up, range is no longer a hindrance and everyone becomes a potential EV buyer.”

Due to its 3D architecture, Prieto’s battery fully charges in three minutes and achieves a 50% charge in 90 seconds, regardless of size.

“A three-minute charge fundamentally changes how companies can design their products and how consumers use them,” added Rosenberg.

All-Weather Extreme Temperature Operation

The Prieto 3D battery delivers the industry’s widest temperature operation. Not only does it operate at -30 degrees C (-22 degrees F), but it also charges at that temperature. The battery also operates and is safe at temperatures as high as +100 degrees C (212 degrees F).

“Prieto’s battery is the only battery that we are aware of that will not only operate, but will also charge at -30 degrees Celsius,” explained Rosenberg. “As we learned this past winter when extreme cold weather hit North America, many people were left stranded with dead EVs. Our battery would have allowed these EVs to continue to operate and charge, instilling confidence in drivers to rely on their EVs even in extreme temperatures.”

Nonflammable

Prieto’s 3D architecture and design ensure that the battery is not flammable or combustible. A third-party lab conducted the gold standard “nail penetration test” on Prieto’s battery that resulted in no fire or explosion, and the battery continued to operate.

“Prieto’s battery operates safely and will not catch fire like traditional lithium-ion batteries,” Rosenberg said. “The 3D architecture and the materials we use ensure that our batteries will not experience thermal runaways or fires, which gives consumers peace of mind.”

3D Interdigitated Technology

“Our founder, Dr. Amy Prieto, reimagined the entire architecture of a conventional battery and developed the first 3D interdigitated battery,” said Rosenberg. “We’re introducing a better architecture and a better process, which results in a better battery and a superior consumer experience. This is truly the next evolution that will redefine the way we power our lives.”

Prieto’s 3D architecture is completely different from all other batteries. Today’s batteries use a decades-old 2D architecture that must always compromise between energy storage and fast charging. In 2D batteries, energy can only flow in one direction across a two-dimensional plane. To charge, lithium ions must flow from one surface to the other, resulting in serious limitations. Thicker 2D batteries store more energy, but the long ion pathways result in slow charging. Thinner 2D batteries can charge faster but cannot store much energy.

“We’ve dramatically shortened the diffusion length in any direction, which takes charging to hyper-speed and delivers more power and energy storage than 2D batteries,” said Dr. Prieto, founder and chief technology officer of Prieto. “The core of our battery looks like a thin copper sponge, and the ions only have to travel from one strand to the next, a fraction of the distance in traditional 2D batteries.”

Prieto’s battery is designed to deliver five times the power density (20C discharge rate) and up to three times the energy density of conventional 2D batteries. It is customizable to any size or application, making it ideal for anything from electric vehicles to power tools, medical devices to mobile phones and small home appliances.

Simple, Cost-Effective Manufacturing

Prieto’s new battery boasts a unique manufacturing advantage because it is made from low-cost, sustainable materials with a simple and scalable process. Prieto uses a proven water-based electroplating process at room temperature and its process requires no dry rooms, clean rooms, or other expensive equipment.

“From day one I prioritized manufacturing ahead of the battery design, and I knew to reimagine the battery we would first have to simplify production to scale up quickly, efficiently, and affordably,” said Dr. Prieto.

Prieto’s current laboratory manufacturing yield rates are more than 90%.

“We now turn our focus to commercialization as we finalize plans to build our pilot manufacturing facility,” said Rosenberg. “Our high yield rates, combined with our simple and familiar manufacturing process used in many other industries, will ultimately result in much lower costs than traditional lithium-ion batteries and gives us a great degree of confidence.”

Prieto is currently in discussions for manufacturing and applications with potential partners.

About Prieto

Prieto developed a proprietary 3D interdigitated lithium-ion battery that delivers transformational performance, such as hyper-fast charging, wide temperature operations and is safe, at a competitive cost. Its battery is customizable to all shapes and sizes for use in electric vehicles, consumer electronics and commercial equipment. Prieto also patented a unique electroplating manufacturing process that uses non-toxic materials without the need for highly specialized facilities. The company was founded in 2009. Prieto’s lab and headquarters are in Fort Collins, Colorado. Visit prietobattery.com.

About Dr. Amy Prieto

Dr. Prieto is the founder and chief technology officer at Prieto. She earned her doctorate in Chemistry from the University of California, Berkeley, and completed her postdoctoral work at Harvard University. She received the Presidential Early Career Award for Scientists and Engineers for this battery technology and is recognized by the Smithsonian Institution, where her innovation is on display in its museum in Washington, D.C.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lisa Metzger
lisametzger@avocetcommunications.com

John Hall
john@avocetcommunications.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye